Here are the S-3 shelf registrations from OnKure Therapeutics, Inc. (OKUR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow OKUR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OKUR filings page.
OnKure Therapeutics, Inc. has filed a shelf registration to permit the resale by selling stockholders of up to 36,144,595 shares of Class A common stock. The shares consist of 26,713,638 outstanding shares and 9,430,957 shares issuable upon exercise of pre-funded warrants issued in a private placement closed March 31, 2026. The company states it will not receive proceeds from resales under this prospectus; however, it will receive proceeds if pre-funded warrants are exercised for cash. The prospectus notes 40,395,480 shares outstanding as of April 1, 2026 and a Beneficial Ownership Limitation tied to pre-funded warrant exercises (default 19.99%).